<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        27-271-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        EPIVAL 200MG\5ML SYRUP
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VALPROATE SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Syrup
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        7.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="UNITED PHARMACEUTICAL COMPANY" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            UNITED PHARMACEUTICAL COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            UNITED PHARMACEUTICAL CO.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AG01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pharmacotherapeutic group:<br />EPIVAL&reg; Syrup contains a medicine called sodium valproate. This belongs to a group of medicines called anti-convulsants or anti-epileptic agents. It works by helping to calm the brain down.<br />Therapeutic indications:<br />EPIVAL&reg; Syrup is used to treat epilepsy (fits) in adults and children.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a. Do not take EPIVAL&reg;</strong><br />Do not take this medicine and tell your doctor if:<br />&bull; You are allergic (hypersensitive) to sodium valproate or any of the other ingredients of EPIVAL&reg; Syrup<br />&bull; Signs of an allergic reaction include: a rash, swallowing or breathing problems, swelling of your lips, face, throat or tongue.<br />&bull; You have liver problems or you or your family have a history of liver problems.<br />&bull; You have a rare illness called porphyria<br />Do not take this medicine if any of the above applies to you. If you are not sure, talk to your doctor or pharmacist before taking EPIVAL&reg; Syrup.</p><p><br /><strong>b. Take special care with EPIVAL&reg;</strong><br />A small number of people being treated with anti-epileptics such as sodium valproate have had thoughts of harming or killing themselves. If at any time you have these thoughts, immediately contact your doctor.<br />Check with your doctor or pharmacist before taking this medicine if:<br />&bull; You have diabetes. This medicine may affect the results of urine tests<br />&bull; You have kidney problems. Your doctor may give you a lower dose<br />&bull; You have fits (epilepsy), brain disease or a metabolic condition affecting your brain.<br />&bull; You have a &lsquo;urea cycle disorder&rsquo; where too much ammonia builds up in the body.<br />&bull; You have an illness called &ldquo;systemic lupus erythematosus (SLE)&rdquo; - a disease of the immune<br />system which affects skin, bones, joints and internal organs<br />If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before taking EPIVAL&reg; Syrup.<br />Weight gain<br />Taking EPIVAL&reg; Syrup may make you put on weight. Talk to your doctor about how this will affect you.<br />Blood tests<br />Your doctor may wish to do blood tests before you start taking EPIVAL&reg; Syrup and during<br />your treatment.</p><p><br /><strong>c. Taking other medicines, herbal or dietary supplements</strong><br />Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines. This includes medicines you buy without a prescription, including herbal medicines.<br />This is because EPIVAL&reg; Syrup can affect the way some other medicines work. Also some medicines can affect the way EPIVAL&reg; Syrup works.<br />The following medicines can increase the chance of you getting side effects, when taken with EPIVAL&reg; Syrup:<br />&bull; Some medicines used for pain and inflammation (salicylates) such as aspirin.<br />&bull; Some other medicines used to treat fits (epilepsy). This includes medicines such as phenobarbital,<br />primidone, phenytoin, carbamazepine, lamotrigine and felbamate<br />EPIVAL&reg; Syrup may increase the effect of the following medicines:<br />&bull; Medicines used for thinning the blood (such as warfarin)<br />&bull; Zidovudine used to treat HIV infection<br />&bull; Temozolomide used to treat cancer<br />&bull; Medicines for depression<br />&bull; Monoamine oxidase inhibitors (MAOI) such as moclobemide, selegiline, linezolid<br />&bull; Medicines used to calm emotional and mental conditions such as diazepam and Olanzapine<br />The following medicines can affect the way EPIVAL&reg; Syrup works:<br />&bull; Some medicines used for the prevention and treatment of malaria such as mefloquine and chloroquine<br />&bull; Cimetidine used for stomach ulcers<br />&bull; Carbapenem agents (antibiotics used to treat bacterial infections) such as imipenem, meropenem, rifampicin and erythromycin. The combination of EPIVAL&reg; Syrup and carbapenems<br />should be avoided because it may decrease the effect of your medicine.<br />&bull; Colestyramine used to lower blood fat (cholesterol) levels</p><p><br /><strong>d. Taking EPIVAL&reg; with food and drink</strong><br />Alcohol intake is not recommended during treatment.<br />e. Pregnancy and breast-feeding<br />Women who could become pregnant:<br />You should not take this medicine if you are pregnant or a women of child-bearing age unless explicitly advised by your doctor.<br />Before you start taking EPIVAL&reg; Syrup, your doctor should discuss with you the possible problems when it is taken in pregnancy.<br />&bull; Unplanned pregnancy is not desirable in women taking EPIVAL&reg; Syrup.<br />&bull; You should use an effective method of contraception and talk to your doctor before planning</p><p><br /><strong>pregnancy</strong>.<br />&bull; EPIVAL&reg; Syrup has no effect on how well the oral contraceptive pill works.<br />Well before you become pregnant it is important to discuss pregnancy and epilepsy with your doctor and, if you have one, your epilepsy specialist. This is to make sure that you and your doctor agree that you should have EPIVAL&reg; if you become pregnant.<br />Women taking EPIVAL&reg; during pregnancy have a higher risk than other women of having a child with an abnormality. The chance of abnormalities is increased if you are also taking other medicines for epilepsy at the same time. These abnormalities include:<br />&bull; Head and face deformities including cleft palate (a gap or depression in the lip)<br />&bull; Deformities of the bones, including hip dislocation<br />&bull; Malformations of the arms and legs<br />&bull; Deformities of the tube from the bladder to the penis, where the opening is formed in a different place<br />&bull; Heart and blood vessel malformations, including heart defects<br />&bull; Defects of the lining of the spinal cord<br />&bull; An abnormality of the spinal cord called &lsquo;Spina bifida&rsquo;<br />&bull; Malformations of the urethra<br /><strong>Women who take EPIVAL&reg; Syrup during pregnancy may be more likely to have a baby with spina bifida.</strong><br />Taking folic acid 5mg each day as soon as you stop contraception may lower the risk of having a baby with spina bifida.<br />There is also an increased risk of other birth defects.<br />These other defects can usually be detected in the first 3 months of the pregnancy using routine antenatal screening blood tests and ultrasound scans.<br />Pregnant mothers who take EPIVAL&reg; Syrup may have babies with:<br />&bull; Blood clotting problems (such as blood not clotting or not clotting very well). This may appear as bruising or bleeding which takes a long time to stop.<br />&bull; Hypoglycaemia (low blood sugar)<br />&bull; Hypothyroidism (underactive thyroid gland, which can cause tiredness or weight gain)<br />Some babies born to mothers who took EPIVAL&reg; Syrup during pregnancy may develop less quickly than normal or have autistic disorders. These children may require additional educational support.<br />Talk to your doctor before you stop taking EPIVAL&reg; if you want to become pregnant. Do not stop taking EPIVAL&reg; suddenly, as it is likely that your fits will come back.<br /><strong>Women who are planning to get Pregnant</strong><br />If you become pregnant, think you may be pregnant or plan to become pregnant while taking EPIVAL&reg; Syrup, you must tell your doctor straight away.<br />&bull; Your doctor will give you appropriate counselling and will suggest changes to your treatment<br />or dose<br />&bull; He or she will also want to check your progress while you are pregnant<br />It is very important that you discuss your treatment with your doctor well before you become<br />pregnant.<br /><strong>Breast-feeding</strong><br />Very little EPIVAL&reg; Syrup gets into the breast milk. However, talk to your doctor about whether you should breast-feed your baby.<br />Ask your doctor or pharmacist for advice before taking any medicine.</p><p><br /><strong>f. Driving and using machines</strong><br />You may feel sleepy when taking EPIVAL&reg; Syrup. If this happens to you, do not drive or use any tools or machines. Taking other medicines used to treat fits or calm emotional and mental health problems may increase sleepiness.</p><p><br /><strong>g. Important information about some of the ingredients of EPIVAL&reg;</strong><br />This medicine contains Sucrose, people with diabetes need to take this into account.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take EPIVAL&reg; Syrup exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.<br />Taking this medicine<br />&bull; Your doctor will decide how much EPIVAL&reg; Syrup to give you or your child depending on you or your child&rsquo;s body weight<br />&bull; Take this medicine by mouth<br />&bull; Take EPIVAL&reg; Syrup with or after food. This will help to stop the feelings of sickness that may happen after taking EPIVAL&reg; Syrup</p><p>&bull; Only dilute the syrup if your doctor or pharmacist tells you to.<br />&bull; If you feel the effect of your medicine is too weak or too strong, do not change the dose yourself but ask your doctor<br /><strong>How to take this medicine</strong><br />&bull; Take this in 2 separate doses - half in the morning and half in the evening.<br />&bull; You will be able to measure the dose using the dosing spoon supplied with the syrup.<br />&bull; If the dose is less than 5ml (200mg), talk to your doctor or pharmacist about how to measure the dose.<br /><strong>How much to take</strong><br />Adults (including the elderly)<br />&bull; The starting dose is 600mg daily. Your doctor should gradually increase this dose by 200mg every 3 days depending on your condition<br />&bull; The usual dose is between 1000mg and 2000mg (20-30mg per kilogram of body weight) each day<br />&bull; This may be increased to 2500mg each day depending on your illness<br />Children over 20 kilograms<br />&bull; The starting dose should be 400mg daily. Your doctor should increase this dose depending on your child&rsquo;s illness<br />&bull; The usual dose is then between 20 mg and 30mg for each kilogram of body weight each day<br />&bull; This may be further increased to 35mg for each kilogram of body weight each day depending on your child&rsquo;s illness.<br />Children under 20 kilograms<br />&bull; The usual dose is 20mg for each kilogram of body weight each day<br />&bull; Depending on the child&rsquo;s condition your child&rsquo;s doctor may decide to increase this dose<br />Patients with kidney problems<br />&bull; Your doctor may decide to adjust your or your child&rsquo;s dose<br />Patients taking other medicines for &lsquo;fits&rsquo; (epilepsy)<br />&bull; You or your child may be taking other medicines for epilepsy at the same time as EPIVAL&reg; Syrup. If so, your doctor should gradually initiate treatment depending on you or your child&rsquo;s condition<br />&bull; Your doctor may increase the dose of EPIVAL&reg; Syrup by 5 to 10mg for each kilogram of body weight each day depending on which other medicines you are taking.<br /><strong>Tests</strong><br />Make sure you or your child keep your regular appointments for a checkup. They are very important as you or your child&rsquo;s dose may need to be changed. EPIVAL&reg; Syrup can change the levels of liver enzymes shown up in blood tests. This can mean that you or your child&rsquo;s liver is not working properly.<br />If you or your child go into hospital or visit another doctor or a dentist, tell them you are taking EPIVAL&reg; Syrup.</p><p><br /><strong>a. If you take more EPIVAL&reg; than you should</strong><br />If you take more EPIVAL&reg; Syrup than you should, tell a doctor or go to a hospital casualty department straight away. Take the medicine pack with you. This is so the doctor knows what you have taken.<br />The following effects may happen: feeling sick or being sick, pupils of the eye become smaller, dizziness, loss of consciousness, weak muscles and poor reflexes, breathing problems, headaches, fits (seizures), confusion, memory loss and unusual or inappropriate<br />behavior.<br /><strong>b. If you forget to take EPIVAL&reg;</strong><br />If you forget to take a dose, take it as soon as you remember. However, if it is nearly time for the next dose, skip the missed dose.<br />Do not take a double dose to make up for a forgotten dose.<br /><strong>c. If you stop taking EPIVAL&reg;</strong><br />Keep taking until your doctor tells you to stop. Do not stop taking EPIVAL&reg; Syrup just because you feel better. If you stop your fits may come back.<br />If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, EPIVAL&reg; Syrup can cause side effects, although not everybody gets them.<br />Tell your doctor straight away if you notice any of the following serious side effects - you may need urgent medical treatment:<br />&bull; You have an allergic reaction. The signs may include: a rash, joint pain, fever (systemic lupus erythematosus), swallowing or breathing problems, swelling of your lips, face, throat or tongue.<br />Hands, feet or genitals may also be affected. More severe allergic reactions can lead to lymph node enlargement and possible impairment of other organs.<br />&bull; Liver problems and problems of the pancreas may show as a sudden illness which may happen in the first six months of treatment. This happens in a very small number of people taking EPIVAL&reg; Syrup. It includes feeling and being sick many times, being very tired, sleepy and weak, stomach pain including very bad upper stomach pain, jaundice (yellowing of the skin or whites of the eyes), loss of appetite, swelling (especially of the legs and feet but may include other parts of the body), worsening of your fits or a general feeling of being unwell<br />&bull; Your doctor may tell you to stop taking EPIVAL&reg; Syrup immediately if you have these symptoms<br />&bull; You have a skin rash or skin lesions with a pink/red ring and a pale centre which may be itchy, scaly or filled with fluid. The rash may appear especially on the palms or soles of your feet. These could be signs of a serious allergy to the medicine called &lsquo;erythema multiforme&rsquo;<br />&bull; Blistering or bleeding of the skin around the lips, eyes, mouth, nose and genitals. Also flu-like symptoms and fever. This may be something called &lsquo;Stevens-Johnson syndrome&rsquo;</p><p>&bull; Severe blistering rash where layers of the skin may peel off to leave large areas of raw exposed skin over the body. Also a feeling of being generally unwell, fever, chills and aching muscles. This may be something called &lsquo;Toxic epidermal necrolysis&rsquo;<br />&bull; Bruising more easily and getting more infections than usual. This could be a blood problem called &lsquo;thrombocytopenia&rsquo;. It can also be due to a fall in the number of white blood cells, bone marrow depression or another condition that affects red blood cells, white blood cells and platelets (pancytopenia) or how the blood clots<br />&bull; Blood clotting problems (bleeding for longer than normal), bruising or bleeding for no reason<br />&bull; Changes in mood, loss of memory, lack of concentration and deep loss of consciousness (coma)<br />&bull; Underactive thyroid gland, which may cause tiredness or weight gain (hypothyroidism)<br />&bull; Breathing difficulty and pain due to inflammation of the lungs (pleural effusion)</p><p>Tell your doctor as soon as possible if you have any of the following side effects:<br />&bull; Changes in behaviour including being very alert, and sometimes also aggressive, hyper-active and unusual or inappropriate behaviour. This is more likely if other medicine to treat fits such as phenobarbital are taken at the same time or if the EPIVAL&reg; Syrup starting dose is high or has been suddenly increased.<br />&bull; Changes in the amount of ammonia in the blood. Symptoms of this condition are being sick, problems with balance and co-ordination, feeling lethargic or less alert<br />&bull; Feeling shaky (tremor), sleepy or unsteady when walking or jerky muscle movements<br />&bull; Feeling tired or confused with loss of consciousness sometimes accompanied by hallucinations or fits<br />&bull; Blisters with the skin flaking away<br />&bull; Rapid, uncontrollable movement of the eyes</p><p>Tell your doctor or pharmacist if any of the following side effects get serious or lasts longer than a few days, or if you notice any side effects not listed in this leaflet:<br />Feeling sick, stomach ache or diarrhoea, especially when starting treatment. This may be helped by taking EPIVAL&reg; Syrup with food or by taking Sodium Valproate Gastro-resistant Tablets instead<br />&bull; Fainting<br />&bull; Hearing loss<br />&bull; Skin problems such as rashes. These happen rarely, but more often in people also taking lamotrigine<br />&bull; Acne<br />&bull; Hair loss which is usually temporary. When it grows back it may be more curly than before<br />&bull; Hair, including body or facial hair grows more than normal in women<br />&bull; Skin rash caused by narrow or blocked blood vessels (vasculitis)<br />&bull; Changes in women&rsquo;s periods and increased hair growth in women<br />&bull; Breast enlargement in men<br />&bull; Swelling of the feet and legs (oedema)<br />&bull; Weight gain - as your appetite may be increased<br />&bull; Kidney problems, bedwetting or increased need to pass urine<br />&bull; Headache<br />&bull; Aggression, agitation, disturbance in attention, abnormal behaviour, restlessness/hyperactivity, and learning disorder<br />&bull; Tingling or numbness in the hands and feet</p><p>Bone Disorders<br />There have been reports of bone disorders including osteopenia and osteoporosis (thinning of the bone) and fractures. Check with your doctor or pharmacist if you are on long-term antiepileptic medication, have a history of osteoporosis, or take steroids.</p><p>Blood tests<br />EPIVAL&reg; Syrup can change levels of liver enzymes, salts or sugars shown up on blood and urine tests.<br />Male Fertility<br />Taking EPIVAL&reg; Syrup can be a contributing factor in male infertility.<br />Talk to your doctor or pharmacist if any of the side effects gets serious or lasts longer than a few days, or if you notice any side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Keep out of the reach and sight of children.<br />- Store below 30&deg; C. Discard the content after one month from first opening.<br />- Do not use EPIVAL&reg; after the expiry date (Exp. Date) which is stated on the outer pack. The expiry date refers to the last day of that month.<br />- Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; The active substance: Sodium Valproate.<br />&bull; Each teaspoonful (5 ml) contains Sodium Valproate 200 mg.<br />&bull; The other ingredients are: Sucrose, Usacert FD&amp;C red No. 40, Cherry Flavor Liquid &amp; Purified Water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                - Dosage form: Syrup.
- Physical Description: Pink, slightly viscous syrup with cherry flavor.
- EPIVAL® Syrup is available in bottles of 100 ml.
- EPIVAL® 200mg/5ml Syrup is packed in Amber glass bottles type III soda lime glass, white cylindrical, Polypropylene inner and outer caps, LD polypropylene ring and insert, child resistant, the bottles are labeled with colored adhesive labels packaged in carton boxes
with a multi folded leaflets & a Translucent polypropylene dosing spoon.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The United Pharmaceutical Mfg. Co. Ltd.<br />P.O. Box 69, Amman 11591-Jordan<br />Tel: + 962 (6) 416 2901<br />Fax: + 962 (6) 416 2905<br />E-mail: info@upm.com.jo</p><p>&nbsp;</p><p>For any information about this medicinal product, please contact the local representative of the Marketing Authorization Holder:<br />Cigalah Group<br />P.O. Box 19435, Jeddah 21435 -KSA<br />Tel: +966126136740<br />Fax: + 96626148458<br />E-mail: ihamidaddin@cigalah.com.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 11/2012; version number: M3-14-1011
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>- المجموعة الدوائية:</p><p>يحتوي إپيڤال شراب على مادة تسمى فالبروات الصوديوم. ينتمي إلى مجموعة من الأدوية تسمى مضادات الصرع أو مضادات التشنجات. يعمل من خلال تهدئة نشاط الدماغ.</p><p>- الاستعمالات العلاجية:</p><p>يستعمل إپيڤال شراب لعلاج الصرع لدى البالغين والأطفال.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>أ. موانع استعمال إپيڤال</strong></p><p>لا تأخذ هذا الدواء وأخبر طبيبك إذا كنت تعاني من:</p><p>&bull; الحساسية (فرط الحساسية) لمادة فالبروات الصوديوم أو لأي من المكونات الأخرى الموجودة في إپيڤال شراب.&nbsp;</p><p>&bull; تتضمن علامات ردود الفعل التحسسي: طفح جلدي، مشاكل في البلع أو التنفس، تورم الشفاه، الوجه، الحلق أو اللسان.&bull; إذا كنت تعاني من مشاكل في الكبد أو إذا كنت تعاني تاريخ مرضي عائلي</p><p>&bull; إذا كنت تعاني من مرض نادر يسمى البورفيريا.</p><p>لا تأخذ هذا الدواء إذا كان أي مما سبق ينطبق عليك. إذا لم تكن متأكدا، يجب عليك التحدث مع طبيبك أو الصيدلاني قبل تناول إپيڤال شراب.</p><p>&nbsp;</p><p><strong>ب. الاحتياطات عند استعمال إپيڤال </strong></p><p>عانى عدد قليل من الناس الذين يتم علاجهم باستعمال مضادات الصرع مثل فالبروات الصوديوم من أفكار إيذاء أو قتل أنفسهم. في أي وقت إذا كنت تعاني هذه الأفكار، اتصل بطبيبك على الفور.</p><p><strong>تحدث إلى طبيبك أو الصيدلاني قبل تناول إپيڤال إذا: </strong></p><p>&bull; كنت تعاني من مرض السكري. قد يؤثر هذا الدواء على نتائج اختبارات البول.</p><p>&bull; كنت تعاني من مشاكل في الكلى. قد يصف لك الطبيب جرعة أقل.</p><p>&bull; كنت تعاني من نوبات صرع، أمراض في الدماغ أو حالات أيضية تؤثر على الدماغ.</p><p>&bull; كنت تعاني من &quot;اضطراب في دورة اليوريا&quot; - حيث يتجمع الكثير من الأمونيا في الجسم.</p><p>&bull; كنت تعاني من مرض يسمى &quot;الذئبة&quot; - وهو مرض في الجهاز المناعي بحيث يصيب الجلد والعظام والمفاصل والاعضاء الداخلية.</p><p>تحدث إلى طبيبك أو الصيدلاني قبل تناول إپيڤال شراب إذا لم تكن متأكداً أن الحالات السابقة تنطبق عليك.</p><p><strong>زيادة الوزن </strong></p><p>يمكن أن يزيد إپيڤال شراب من شهيتك ويسبب في زيادة وزنك. يجب التحدث مع طبيبك حول كيفية تأثير هذا عليك.</p><p><strong>اختبارات الدم </strong></p><p>قد يرغب طبيبك بإجراء اختبارات الدم قبل البدء بتناول إپيڤال شراب وخلال فترة العلاج.</p><p>&nbsp;</p><p><strong>ج. التداخلات الدوائية من تناول هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p>من فضلك، أخبر طبيبك أو الصيدلاني إذا كنت تتناول أو تناولت مؤخرا أي أدوية أخرى، بما في ذلك الأدوية التي يتم الحصول عليها دون وصفة طبية. يشمل هذا الأدوية العشبية. وذلك لأن إپيڤال شراب يمكن أن يؤثر على الطريقة التي تعمل بها بعض الأدوية الأخرى. أيضا بعض الأدوية يمكن أن تؤثر على طريقة عمل إپيڤال شراب.</p><p><strong>يمكن أن تزيد الأدوية التالية من فرصة حدوث آثار جانبية، عند تناولها مع إپيڤال شراب:</strong></p><p>&bull; بعض الأدوية المستعملة لعلاج الألم والالتهاب الساليسيلات مثل الأسبرين.</p><p>&nbsp;&bull; بعض الأدوية الأخرى المستعملة لعلاج نوبات الصرع . وهذا يشمل الأدوية مثل فينوباربيتال، بريميدون، الفينيتوين، كاربامازيبين، لاموتريجين و فيلبامات.</p><p><strong>قد يزيد إپيڤال شراب من تأثير الأدوية التالية: </strong></p><p>&bull; أدوية تقليل لزوجة الدم مثل الوارفارين.</p><p>&bull; زيدوفودين &ndash; لعلاج فيروس نقص المناعة البشرية والإيدز.</p><p>&bull; تيموزولومايد &ndash; لعلاج السرطان.</p><p>&bull; أدوية لعلاج الاكتئاب</p><p>&bull; مثبطات مونو أمين أوكسيديز MAOI مثل موكلوبميد، سيليجيلين، لينزولايد.&nbsp;</p><p>&bull; الأدوية المستعملة لتهدئة الحالات العاطفية والعقلية مثل الديازيبام والأولانزابين</p><p><strong>يمكن أن تؤثر الأدوية التالية على الطريقة التي يعمل بها إپيڤال شراب:</strong></p><p>&bull; بعض الأدوية المستعملة للوقاية وعلاج الملاريا مثل الميفلوكين والكلوروكين.</p><p>&bull; سيميتيدين &ndash; لعلاج قرحة المعدة.</p><p>&bull; أدوية الكاربامينيم مضادات حيوية تستعمل لعلاج الالتهابات البكتيرية مثل إميبينيم، ميروبينيم، ريفامبيسين ()وإريثروميسين. يجب تجنب تزامن العلاج بين إپيڤال شراب و الكاربامينيم لأنه قد يقلل من تأثير الدواء الخاص بك.</p><p>&bull; الكولسترامين &ndash; لعلاج ارتفاع مستويات الدهون في الدم.</p><p><strong>د. تناول إپيڤال مع الطعام والشراب </strong></p><p>لا يوصى بشرب الكحول خلال فترة العلاج.</p><p>&nbsp;</p><p><strong>هـ. الحمل والرضاعة</strong></p><p>النساء اللواتي قد يحملن يجب عدم تناول هذا الدواء إذا كنت امرأة حامل أو في سن الإنجاب، إلا إذا قمتي باستشارة الطبيب.</p><p>قبل البدء في تناول إپيڤال شراب، يجب أن يناقش الطبيب معك المشاكل المحتملة عند تناوله أثناء الحمل.</p><p>&bull; الحمل غير المخطط له غير مرغوب فيه في النساء اللاتي يتناولن على إپيڤال شراب.</p><p>&bull; يجب استعمال وسيلة فعالة لمنع الحمل والتحدث مع الطبيب قبل التخطيط للحمل.</p><p>&bull; إن إپيڤال شراب ليس له تأثير على كيفية عمل أقراص منع الحمل الفموية.</p><p>من المهم مناقشة الحمل والصرع مع الطبيب، أخصائي الصرع الخاص بك، جيدا قبل أن تصبحي حاملا. هذا للتأكد من أنك والطبيب توافقون على تناول إپيڤال شراب عند حدوث الحمل.</p><p>إن تناول إپيڤال في النساء خلال فترة الحمل لديهن زيادة في احتمالية إنجاب طفل يعاني من تشوهات.</p><p>تزداد فرصة حدوث تشوهات إذا كنت تتناولين أيضا أدوية مضادة للصرع أخرى في نفس الوقت.</p><p>وتشمل هذه التشوهات:</p><p>&bull; تشوهات في الرأس و الوجه بما في ذلك الشق الحلقي وجود فجوة أو انخفاض في الشفة.</p><p>&bull; تشوهات في العظام، بما في ذلك خلع الورك.</p><p>&bull; تشوهات الذراعين والساقين.</p><p>&bull; تشوهات في أنابيب المثانة إلى القضيب أو المهبل، مع تشكيل فتحات إضافية.</p><p>&bull; تشوهات في القلب والأوعية الدموية وعيوب خلقية في القلب.</p><p>&bull; تشوهات في بطانة الأنابيب العصبية مع ثقوب أو نتوءات.</p><p>&bull; عيوب بطانة الحبل الشوكي.</p><p>&bull; وجود خلل في النخاع الشوكي يسمى&Prime; السنسنة المشقوقة &Prime;.</p><p>&bull; تشوه في الإحليل.</p><p>النساء اللاتي يتناولن إپيڤال شراب أثناء الحمل قد تكن أكثر عرضة لإنجاب أطفال يعانون من الصلب المشقوق.</p><p>إن تناول حمض الفوليك يومياً بجرعة 5ملغم عند توقف تناول أقراص منع الحمل قد تقلل من خطر إنجاب طفل يعانون من الصلب المشقوق.</p><p>هناك أيضا زيادة احتمالية حدوث عيوب خلقية أخرى. عادة يمكن الكشف عن هذه العيوب الأخرى في الثلاث أشهر الأولى من الحمل باستعمال اختبارات روتينية قبل الولادة بفحص الدم وفحص بالأشعة فوق الصوتية.</p><p>الأمهات الحوامل اللاتي يتناولن إپيڤال شراب قد يعاني الأطفال من:</p><p>&bull; مشاكل في تخثر الدم مثل عدم تخثر الدم بشكل جيد. قد تظهر هذه على شكل كدمات أو نزيف يأخذ وقتا طويلا ليتوقف.&nbsp;</p><p>&bull; انخفاض نسبة السكر في الدم.</p><p>&bull; انخفاض في الغدة الدرقية هبوط في الغدة الدرقية، والتي يمكن أن تسبب تعب أو زيادة في الوزن&nbsp;</p><p>بعض الأطفال الذين يولدون لأمهات استعملن إپيڤال شراب أثناء الحمل قد يتطورون بسرعة أقل من المعتاد أو قد يعانون من اضطرابات التوحد.</p><p>قد يتطلب هؤلاء الأطفال الدعم التعليمي الإضافي.</p><p>يجب التحدث مع طبيبك قبل تناول إپيڤال ووقفه إذا كنت تريدين أن تصبح حاملا. من المهم عدم التوقف عن إپيڤال الخاص بك فجأة، لأنه من المرجح أن تعود النوبات الخاص بك.</p><p>النساء اللواتي يخططن لحصول حمل إذا أصبحت حاملا، تعتقدين بأنك قد تكونين حاملا أو تخططين لتصبحي حاملا مع تناول إپيڤال شراب، يجب إخبار الطبيب على الفور.</p><p>&bull; سوف يعطيك طبيبك المشورة المناسبة وسوف يقترح تغيير العلاج أو تعديل الجرعة.</p><p>&bull; سوف تحتاج أو يحتاج أيضا إلى التحقق من سير الحمل.</p><p>من المهم جدا مناقشة العلاج الخاص بك مع الطبيب جيدا قبل أن تصبح حاملا.</p><p><strong>الرضاعة الطبيعية</strong></p><p>يفرز إپيڤال شراب بشكل قليل جدا في حليب الثدي. ومع ذلك، يجب التحدث مع طبيبك حول ما إذا كان يجب إرضاع طفلك.</p><p>إسأل طبيبك أو الصيدلاني للحصول على المشورة قبل تناول أي دواء.</p><p>&nbsp;</p><p><strong>و. القيادة واستعمال الآلات</strong></p><p>قد تشعر بالنعاس عند بدء استعمال إپيڤال شراب. إذا حدث هذا لكم، لا تقم بالقيادة أو استعمال أي أدوات أو آلات. إن تناول أدوية أخرى لعلاج الصرع أو تهدئة الاعصاب والمشاعر قد تسبب النعاس</p><p><strong>ز. معلومات هامة حول بعض مكونات إپيڤال</strong></p><p>يحتوي هذا المستحضر على السكروز، يجب أخذ هذا في الحسبان في المرضى الذين يعانون من داء السكري.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>دائما تناول إپيڤال شراب تماما كما أخبرك طبيبك. يجب التحقق من الطبيب أو الصيدلاني إذا كنت غير متأكد.</p><p><strong>تناول هذا الدواء </strong></p><p>&bull; سوف يقرر لك طبيبك كم كمية إپيڤال شراب التي تحتاجها أو يحتاجها طفلك وفقا لوزن الجسم</p><p>&bull; تناول هذا الدواء عن طريق الفم</p><p>&bull; تناول إپيڤال شراب مع أو بعد وجبة الطعام. يساعد هذا على تقليل احتمالية حدوث بعض الآثار الجانبية مثل الغثيان الذي قد يحدث بعد تناول إپيڤال شراب</p><p>&bull; قم بتخفيف الشراب فقط إذا أخبرك طبيبك أو الصيدلاني بذلك.</p><p>&bull; إذا كنت تشعر بأن تأثير الدواء ضعيف جدا أو قوي جدا، لا تغير الجرعة نفسك ولكن اسأل طبيبك كيفية تناول هذا الدواء</p><p>&bull; تناوله على شكل جرعتين منفصلتين - نصفها في الصباح ونصفها في المساء.</p><p>&bull; يمكن أن تكون قادراً على قياس الجرعة باستعمال ملعقة الجرعات المتوفرة مع شراب</p><p>.&bull; إذا كانت الجرعة أقل من 5مل 200ملغم، تحدث مع طبيبك أو الصيدلاني حول كيفية قياس الجرعة. كم الكمية التي يجب تناولها الكبار ويشمل كبار السن<br />&nbsp;&bull; تبلغ الجرعة الابتدائية 600 ملغم يوميا.</p><p>يجب على طبيبك زيادة الجرعة تدريجيا بمقدار 200ملغم كل 3 أيام اعتمادا على حالتك</p><p>&bull; تبلغ الجرعة الإعتيادية بين 1000 و 2000 ملغم 20-30 ملغم / كلغم من وزن الجسم كل يوم</p><p>&bull; يمكن زيادة ذلك إلى 2500 ملغم كل يوم اعتمادا على درجة مرضك</p><p><strong>الأطفال ذوو وزن أكثر من 20كلغم:</strong></p><p>&bull; يجب أن تبدأ الجرعة ب 400 ملغم يوميا. يجب على الطبيب زيادة الجرعة بالاعتماد على درجة مرض طفلك</p><p>&bull; تبلغ الجرعة الاعتيادية ما بين 20 و 30ملغم لكل كيلوغرام من وزن الجسم.</p><p>&bull; يمكن زيادة هذه الجرعة إلى 35ملغم لكل كيلوغرام من وزن الجسم يومياً بالاعتماد على درجة مرض طفلك.</p><p><strong>الأطفال ذوو وزن أقل من 20كلغم:</strong></p><p>&bull; تبلغ الجرعة الاعتيادية 20ملغم لكل كيلوغرام من وزن الجسم.</p><p>&bull; بالاعتماد على حالة طفلك قد يقرر الطبيب زيادة الجرعة. الأشخاص الذين يعانون من مشاكل في الكلى</p><p>&bull; قد يقرر طبيبك تعديل الجرعة لك أو لطفلك. المرضى الذين يتناولون أدوية أخرى لعلاج نوبات الصرع</p><p>&bull; إذا كنت أنت أو طفلك تتناولون أدوية أخرى لعلاج الصرع في نفس الوقت الذي تتناولون به إپيڤال شراب. إذا كان الأمر كذلك، يجب على الطبيب بدء العلاج تدريجيا وفقا لحالتك أو حالة طفلك</p><p>&bull; قد يزيد طبيبك جرعة إپيڤال شراب بنسبة 5 إلى 10 ملغم لكل كيلوغرام من وزن الجسم كل يوم اعتمادا على نوع الدواء الذي تأخذونه</p><p><strong>.الفحوص</strong></p><p>تأكد من الحفاظ على مواعيد الفحص العادية. فهي مهمة جدا لأن الجرعة قد تحتاج إلى تغيير. قد يغير إپيڤال شراب من مستويات انزيمات الكبد التي تظهر في فحوص المختبر. قد يعني ذلك بأن الكبد لا يعمل بشكل جيد.</p><p>إذا ذهبت إلى المستشفى أو زيارة طبيب آخر أو إلى طبيب الأسنان، يجب إعلامهم بأنك تتناول إپيڤال شراب.</p><p><strong>إذا تناولت إپيڤال أكثر مما يجب</strong></p><p>إذا كنت تعتقد بأنك قد تناولت إپيڤال شراب أكثر مما يجب، أخبر الطبيب أو اذهب مباشرة لطوارىء المستشفى. خذ العبوة معك حتى يعرف الأطباء ما قد تناولته. قد تحدث الآثار التالية:</p><p>الشعور بالغثيان أو القيء، بؤبؤ العين قد يصبح أصغر حجما، الدوخة، فقدان الوعي، ضعف العضلات وردود فعل سيئة، مشاكل في التنفس، صداع، نوبات التشنجات، ارتباك، فقدان الذاكرة وسلوك غير عادي أو غير لائق.</p><p><strong>إذا نسيت تناول إپيڤال</strong></p><p>إذا نسيت تناول الجرعة في الوقت المناسب، خذها في اقرب وقت تذكرتها فيه، إلا إذا حان الوقت تقريبا للجرعة التالية، فقم بالاستغناء عن الجرعة المنسية.لا تأخذ جرعة مضاعفة لتعويض الجرعة المنسية.</p><p><strong>إذا توقفت عن تناول إپيڤال</strong></p><p>استمر في تناول هذا الدواء حتى يخبرك الطبيب بالتوقف عنه. لا تتوقف عن تناول إپيڤال شراب دون مناقشة هذا أولا مع الطبيب الخاص بك، حتى إذا كنت تشعر بتحسن. وذلك لأن التوقف المفاجىء قد يؤدي إلى عودة حدوث النوبات مرة أخرى.</p><p>إذا كان لديك أي أسئلة أخرى عن استعمال هذا المستحضر، أسأل طبيبك أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، فإن إپيڤال شراب يمكن أن يتسبب في إحداث آثار جانبية، على الرغم من أن الجميع لا يصاب بها.</p><p>أخبر طبيبك فورا إذا لاحظت أي من الآثار الجانبية الخطيرة التالية قد تحتاج إلى علاج طبي عاجل:</p><p>&bull; كنت تعاني من تفاعلات تحسسية. يمكن أن تشمل العلامات: طفح جلدي، آلام المفاصل والحمى الذئبة الحمامية الجهازية، مشاكل في البلع أو التنفس، تورم الشفاه والوجه والحلق أو اللسان.</p><p>يمكن أيضا أن تتأثر اليدين والقدمين أو الأعضاء التناسلية. إن التفاعلات التحسسية الأكثر خطورة يمكن أن تؤدي إلى تضخم الغدد اللمفاوية وضعف ممكن من الأجهزة الأخرى.</p><p>&bull; مشاكل في الكبد ومشاكل في البنكرياس قد تظهر على أنها مرض مفاجئ و قد يحدث في الأشهر الستة الأولى من العلاج. يحدث هذا في عدد قليل من الأشخاص الذين يتناولون إپيڤال شراب. فإنه يشمل الشعور بالغثيان مرات عديدة، الشعور بالتعب الشديد، النعاس وضعف وآلام في المعدة بما في ذلك آلام سيئة جدا في الجزء العلوي من المعدة، اليرقان اصفرار الجلد أو بياض العينين، فقدان الشهية، تورم خاصة في الارجل والأقدام وقد تشمل أجزاء اخرى من الجسم، (()) تفاقم الصرع أو شعور عام بعدم الراحة.</p><p>&bull; قد يطلب منك طبيبك التوقف عن تناول إپيڤال شراب فوراً إذا كنت تعاني من هذه الأعراض.</p><p>&bull; إذا كنت تعاني من طفح جلدي أو تقرحات الجلد مع حلقة وردية / حمراء ومركز شاحب والتي قد تكون مثيرة للحكة، متقشرة أو مملوءة بسائل. قد يظهر طفح جلدي وخاصة على الراحتين أو باطن قدميك. يمكن أن تكون هذه دلائل على وجود حساسية خطيرة للدواء تسمى &quot;حمامي متعددة الأشكال&#39;&#39;</p><p>&bull; التقرح أو النزف في الجلد حول الشفتين والعينين والفم والأنف والأعضاء التناسلية. أيضا أعراض تشبه أعراض الانفلونزا والحمى. قد يكون هذا ما يسمى &quot;متلازمة ستيفنز جونسون &quot;</p><p>&bull; طفح جلدي تقشري شديد بحيث تتقشر طبقات الجلد وتترك مناطق واسعة من الجلد معراة في أنحاء الجسم. الشعور بالإعياء أيضا بصفة عامة، حمى، قشعريرة آلام العضلات. قد يكون هذا ما يسمى &quot;انحلال البشرة السمي&quot;</p><p>&bull; حدوث كدمات بسهولة أكبر والحصول على المزيد من الإصابات أكثر من المعتاد. يمكن أن يكون هذا مشكلة في الدم تسمى &Prime;قلة الصفائح الدموية&quot;. يمكن أن يكون بسبب انخفاض في عدد خلايا الدم البيضاء أيضا وهبوط نخاع العظام أو حالة آخرى تؤثر على خلايا الدم الحمراء، خلايا الدم البيضاء والصفائح الدموية.</p><p>&bull; مشاكل في الدم مثل مشاكل تخثر الدم النزيف لفترة أطول من المعتاد، كدمات أو نزيف دون سبب.</p><p>&bull; تغيرات في المزاج، فقدان الذاكرة، عدم القدرة على التركيز وفقدان الوعي العميق غيبوبة</p><p>&bull; هبوط في الغدة الدرقية، والتي قد تسبب التعب أو زيادة الوزن قلة إفرازات الغدة الدرقية</p><p>&bull; صعوبة في التنفس وآلام بسبب التهاب في الرئتين الانصباب الجنبي<br /><strong>أخبر طبيبك في أقرب وقت ممكن إذا كنت تعاني أي من الآثار الجانبية التالية: </strong></p><p>&bull; سلوك غير عادي والذي يتضمن اليقظة، وأحيانا عدوانية أيضا، النشاط المفرط وسلوك سيئ. يمكن أن تترافق مع نوبات متكررة أكثر أو أشد، فقدان الدافع. يحدث هذا على الأرجح عند تناول فينوباربيتال وتوبيراميت بالتزامن أو إذا تم زيادة جرعة إپيڤال شراب فجأة.</p><p>&bull; تغييرات في كمية الأمونيا في الدم. تشمل أعراض هذه الحالة الغثيان، مشاكل في التوازن وتناسق الحركة، الشعور بالكسل وقلة التركيز.</p><p>&bull; نعسان أو عدم استقرار عند المشي أو حركات عضلية متشنجة.</p><p>&bull; الشعور بالتعب، الارتباك، مع فقدان الوعي الغيبوبة مصحوبة أحيانا بالهلوسة أو النوبات.&nbsp;</p><p>&bull; بثور مع تساقط خلايا الجلد بعيدا.</p><p>&bull; حركة سريعة غير مسيطر عليها للعينين.</p><p>أخبر طبيبك أو الصيدلاني إذا كانت أي من الآثار الجانبية التالية خطيرة أو أستمرت لفترة أطول من بضعة أيام، أو إذا لاحظت أي آثار جانبية غير المذكورة في هذه النشرة:</p><p>الشعور بالمرض، ألم في المعدة أو الإسهال، وخاصة عند بدء العلاج. قد يقل هذه من خلال تناول إپيڤال شراب مع الطعام أو عن طريق تناول أقراص الفالبروات الصوديوم مقاومة لاحماض المعدة بدلا عنه</p><p>&bull; الاغماء</p><p>&bull; فقدان السمع</p><p>&bull; مشاكل في الجلد مثل الحكة.</p><p>قد يحدث هذا نادرا ولكن اكثر تواترا مع المرضى الذين يتناولون لاموترجين.</p><p>&bull; حب الشباب</p><p>&bull; فقدان الشعر والذي يكون مؤقت في العادة.</p><p>عندما ينمو مرة أخرى قد يكون أكثر تجعدا من ذي قبل</p><p>&bull; الشعر، بما في ذلك الجسم أو الوجه والشعر ينمو أكثر من المعتاد في النساء</p><p>&bull; الطفح الجلدي الناجم عن الأوعية الدموية الضيقة أو المحظورة التهاب الأوعية الدموية<br />&bull; تغييرات في فترة الطمث المرأة وزيادة نمو الشعر في النساء</p><p>&bull; تضخم الثدي لدى الرجال</p><p>&bull; تورم في القدمين والساقين وذمة<br />&nbsp;&bull; زيادة الوزن - شهيتك قد تزاد</p><p>&bull; مشاكل الكلى، والتبول اللاإرادي أو ازدياد الحاجة لتمرير البول</p><p>&bull; الصداع</p><p>&bull; العدوان، والإثارة، واضطراب الانتباه، والسلوك الشاذ، والأرق / فرط النشاط، واضطراب التعلم</p><p>&bull; وخز أو خدر في اليدين والقدمين</p><p>اضطرابات العظام</p><p>هناك تقارير عن حدوث اضطرابات في العظام بما في ذلك هشاشة وترقق العظام والكسور. استشر طبيبك أو الصيدلاني إذا كنت ستأخذ مضادات الصرع على المدى الطويل، لديك تاريخ مرضي للإصابة بهشاشة العظام، أو تأخذ الستيرويدات.</p><p>فحوص الدم</p><p>قد يغير إپيڤال شراب من انزيمات الكبد، الاملاح او السكر في فحوص الدم والبول.</p><p>خصوبة الذكور</p><p>إن تناول إپيڤال شراب قد يكون عاملا مساعدا في حدوث العقم عند الذكور.</p><p>تحدث إلى طبيبك أو الصيدلاني إذا أصبحت أي من هذه الآثار الجانبية خطيرة أو استمرت لفترة أطول من بضعة أيام، أو إذا لاحظت أي آثار جانبية غير المذكورة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- يحفظ بعيدا عن متناول وبصر الأطفال.</p><p>- يحفظ دون 30&deg; م. تخلص من المحتوى بعد شهر واحد من فتح العبوة لأول مرة.</p><p>-لا تستعمل إپيڤال بعد تاريخ انتهاء الصلاحية التي توضع على العلبة الخارجية.</p><p>يشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر.</p><p>- يجب عدم التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلاني عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. وسوف تساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>أ. ما هي محتويات إپيڤال 200ملغم/5مل شراب</p><p>- المادة الفعالة هي: فالبروات الصوديوم.- كل ملعقة صغيرة 5مل تحتوي على فالبروات الصوديوم 200 ملغم.</p><p>- المكونات الأخرى هي:سكروز، لون احمر، نكهة كرز سائلة وماء نقي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>- الشكل الصيدلاني:</p><p>شراب .</p><p>- الوصف الخارجي:</p><p>شراب زهري مائل للزوجة بطعم الكرز.- متوفر إپيڤال شراب بقنينة سعة 100 مل.</p><p>- معبأة إپيڤال 200ملغم/5مل شراب في قنينة عنبرية اللون مصنوعة من الزجاج النوع الثالث زجاج الصودا الجيري، مع أغطية أسطوانية بيضاء، مصنوعة من مادة البولي بروبيلين داخلي وخارجي، ومختومة بحلقة من مادة بولي بروبلين LD ونشرات طبية، الأغطية مقاومة للطفل، يلصق على القنينة رقعات لاصقة ملونة تعبئ في صناديق كرتونية مع منشورات مطوية متعددة وملعقة شفافة من البولي بروبلين تخص قياس الجرعات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الشركة المتحدة لصناعة الأدوية</p><p>ذ.م.م</p><p>ص.ب. 69، عمان 11591- الأردن</p><p>هاتف: 4162901 6 962+</p><p>فاكس: 4162905 6 962+</p><p>البريد الإلكتروني: info@upm.com.jo</p><p>&nbsp;</p><p>لأي معلومات عن هذا الدواء،</p><p>يرجى الاتصال بالممثل المحلي للشركة مالكة رخصة التسويق:</p><p>مؤسسات سقالة</p><p>ص.ب. 19435،</p><p>جدة 21435-السعودية</p><p>الهاتف: 966126136740+</p><p>فاكس: 96626148458 +</p><p>البريد الإلكتروني: ihamidaddin@cigalah.com.sa<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم الموافقة على هذه النشرة بتاريخ 11/2012؛ رقم النسخة : 1011-14-M


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 EPIVAL® 200mg/5ml Syrup
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Material Name	Amount / one bottle (100ml)
Sodium Valproate	4.10g
Sucrose	80.0g
Usacert FD&C red No. 40	0.0025g
Cherry Flavor Liquid	0.020g
Purified Water Q.S.	100 ml
For a full list of excipients, see section 6.1 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Syrup
EPIVAL® 200mg/5ml Syrup: Pink, slightly viscous syrup with cherry flavor.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the treatment of generalised, partial or other epilepsy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Route of administration: Oral. </strong></p><p>Daily dosage requirements vary according to age and body weight.</p><p><strong>EPIVAL<sup>&reg;</sup></strong> Syrup may be given twice daily. If it is necessary to dilute <strong>EPIVAL<sup>&reg;</sup></strong> Syrup, the recommended diluent is Syrup BP, but syrup containing SO<sub>2</sub>&nbsp;as a preservative should not be used. The diluted product will have a 14-day shelf life.</p><p>In patients where adequate control has been achieved sodium valproate Controlled Release Tablets</p><p>&nbsp;Formulations are interchangeable with other sodium valproate conventional or prolonged release formulations on an equivalent daily dosage basis.</p><p><em>Dosage</em></p><p>Usual requirements are as follows:</p><p><u>Adults</u></p><p>Dosage should start at 600mg daily increasing by 200mg at three-day intervals until control is achieved. This is generally within the dosage range 1000mg to 2000mg per day, ie 20-</p><p>30mg/kg/day body weight. Where adequate control is not achieved within this range the dose may be further increased to 2500mg per day.</p><p><u>Children over 20kg</u></p><p>Initial dosage should be 400mg/day (irrespective of weight) with spaced increases until control is achieved; this is usually within the range 20-30mg/kg body weight per day. Where adequate control is not achieved within this range the dose may be increased to 35mg/kg body weight per day.</p><p><u>Children under 20kg</u></p><p>20mg/kg of body weight per day; in severe cases this may be increased but only in patients in whom plasma valproic acid levels can be monitored. Above 40mg/kg/day, clinical chemistry and haematological parameters should be monitored.</p><p><u>Use in the elderly</u></p><p>Although the pharmacokinetics of <strong>EPIVAL<sup>&reg;</sup></strong> is modified in the elderly, they have limited clinical significance and dosage should be determined by seizure control. The volume of distribution is increased in the elderly and because of decreased binding to serum albumin; the proportion of free drug is increased. This will affect the clinical interpretation of plasma valproic acid levels.</p><p><u>In patients with renal insufficiency</u></p><p>It may be necessary to decrease the dosage. Dosage should be adjusted according to clinical monitoring since monitoring of plasma concentrations may be misleading.</p><p><u>In patients with hepatic insufficiency</u></p><p>Salicylates should not be used concomitantly with <strong>EPIVAL<sup>&reg;</sup></strong> since they employ the same metabolic pathway.</p><p>Liver dysfunction, including hepatic failure resulting in fatalities, has occurred in patients whose treatment included valproic acid.</p><p>Salicylates should not be used in children under 16 years. In addition in conjunction with <strong>EPIVAL<sup>&reg;</sup></strong>, concomitant use in children under 3 years can increase the risk of liver toxicity.</p><p><u>Female children, female adolescents, women of childbearing potential and pregnant women</u></p><p><strong>EPIVAL<sup>&reg;</sup></strong> should be initiated and supervised by a specialist experienced in the management of epilepsy. Treatment should only be initiated if other treatments are ineffective or not tolerated and the benefit and risk should be carefully reconsidered at regular treatment reviews. Preferably <strong>EPIVAL<sup>&reg;</sup></strong> should be prescribed as monotherapy and at the lowest effective dose, if possible as a prolonged release formulation to avoid high peak plasma concentrations. The daily dose should be divided into at least two single doses.</p><p><em>Combined Therapy</em></p><p>When starting <strong>EPIVAL<sup>&reg;</sup></strong>in patients already on other anticonvulsants, these should be tapered slowly: initiation of <strong>EPIVAL<sup>&reg;</sup></strong> therapy should then be gradual, with target dose being reached after about 2 weeks. In certain cases it may be necessary to raise the dose by 5 to 10mg/kg/day when used in combination with anticonvulsants which induce liver enzyme activity, eg phenytoin, phenobarbital and carbamazepine. Once known enzyme inducers have been withdrawn it may be possible to maintain seizure control on a reduced dose of <strong>EPIVAL<sup>&reg;</sup></strong>. When barbiturates are being administered concomitantly and particularly if sedation is observed (particularly in children) the dosage of barbiturate should be reduced.</p><p>NB: In children requiring doses higher than 40mg/kg/day clinical chemistry and haematological parameters should be monitored.</p><p>&nbsp;</p><p>Optimum dosage is mainly determined by seizure control and routine measurement of plasma levels is unnecessary. However, a method for measurement of plasma levels is available and may be helpful where there is poor control or side effects are suspected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Active liver disease
-	Personal or family history of severe hepatic dysfunction, especially drug related
-	Hypersensitivity to sodium valproate
-	Porphyria

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Although there is no specific evidence of sudden recurrence of underlying symptoms following withdrawal of valproate, discontinuation should normally only be done under the supervision of a specialist in a gradual manner. This is due to the possibility of sudden alterations in plasma concentrations giving rise to a recurrence of symptoms. NICE has advised that generic switching of valproate preparations is not normally recommended due to the clinical implications of possible variations in plasma concentrations.</p><p><strong>4.4.1 Special warnings</strong></p><p><strong><em>Liver dysfunction:</em></strong></p><p><u>Conditions of occurrence</u>:</p><p>Severe liver damage, including hepatic failure sometimes resulting in fatalities, has been very rarely reported. Experience in epilepsy has indicated that patients most at risk, especially in cases of multiple anticonvulsant therapy, are infants and in particular young children under the age of 3 years and those with severe seizure disorders, organic brain disease, and (or) congenital metabolic or degenerative disease associated with mental retardation.</p><p>After the age of 3 years, the incidence of occurrence is significantly reduced and progressively decreases with age.</p><p>The concomitant use of salicylates should be avoided in children under 3 years due to the risk of liver toxicity. Additionally, salicylates should not be used in children under 16 years.</p><p>Monotherapy is recommended in children under the age of 3 years when prescribing <strong>EPIVAL<sup>&reg;</sup></strong>, but the potential benefit of <strong>EPIVAL<sup>&reg;</sup></strong> should be weighed against the risk of liver damage or pancreatitis in such patients prior to initiation of therapy.</p><p>In most cases, such liver damage occurred during the first 6 months of therapy, the period of maximum risk being 2-12 weeks.</p><p><u>Suggestive signs</u>:</p><p>Clinical symptoms are essential for early diagnosis. In particular the following conditions, which may precede jaundice, should be taken into consideration, especially in patients at risk:</p><p>- Nonspecific symptoms, usually of sudden onset, such as asthenia, malaise, anorexia, lethargy, oedema and drowsiness, which are sometimes associated with repeated vomiting and abdominal pain.</p><p>- In patients with epilepsy, recurrence of seizures.</p><p>These are an indication for immediate withdrawal of the drug.</p><p>Patients (or their family for children) should be instructed to report immediately any such signs to a physician should they occur. Investigations including clinical examination and biological assessment of liver function should be undertaken immediately.</p><p>&nbsp;</p><p><u>Detection</u>:</p><p>Liver function should be measured before therapy and then periodically monitored during the first 6 months of therapy, especially in those who seem most at risk, and those with a prior history of liver disease.</p><p>Amongst usual investigations, tests which reflect protein synthesis, particularly prothrombin rate, are most relevant.</p><p>Confirmation of an abnormally low prothrombin rate, particularly in association with other biological abnormalities (significant decrease in fibrinogen and coagulation factors; increased bilirubin level and raised transaminases) requires cessation of <strong>EPIVAL<sup>&reg;</sup></strong> therapy.</p><p>As a matter of precaution and in case they are taken concomitantly salicylates should also be discontinued since they employ the same metabolic pathway.</p><p>As with most antiepileptic drugs, increased liver enzymes are common, particularly at the beginning of therapy; they are also transient.</p><p>More extensive biological investigations (including prothrombin rate) are recommended in these patients; a reduction in dosage may be considered when appropriate and tests should be repeated as necessary.</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Pancreatitis:</em></strong>&nbsp;Pancreatitis, which may be severe and result in fatalities, has been very rarely reported. Patients experiencing nausea, vomiting or acute abdominal pain should have a prompt medical evaluation (including measurement of serum amylase).Young children are at particular risk; this risk decreases with increasing age. Severe seizures and severe neurological impairment with combination anticonvulsant therapy may be risk factors. Hepatic failure with pancreatitis increases the risk of fatal outcome. In case of pancreatitis, <strong>EPIVAL<sup>&reg;</sup></strong> should be discontinued.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:716px"><tbody><tr><td style="vertical-align:top"><p><strong>Female children/Female adolescents/Women of childbearing potential/Pregnancy:</strong></p><p><strong>EPIVAL&reg;</strong> should not be used in female children, in female adolescents, in women of childbearing potential and pregnant women unless alternative treatments are ineffective or not tolerated because of its high teratogenic potential and risk of developmental disorders in infants exposed in utero to valproate. The benefit and risk should be carefully reconsidered at regular treatment reviews, at puberty and urgently when a woman of childbearing potential treated with <strong>EPIVAL<sup>&reg;</sup></strong> plans a pregnancy or if she becomes pregnant.</p><p>Women of childbearing potential must use effective contraception during treatment and be informed of the risks associated with the use of <strong>EPIVAL<sup>&reg;</sup></strong> during pregnancy.</p><p>The prescriber must ensure that the patient is provided with comprehensive information on the risks alongside relevant materials, such as a patient information booklet, to support her understanding of the risks.</p><p>In particular the prescriber must ensure the patient understands:</p><p>&bull; The nature and the magnitude of the risks of exposure during pregnancy, in particular the teratogenic risks and the risks of developmental disorders.</p><p>&bull; The need to use effective contraception.</p><p>&bull; The need for regular review of treatment.</p><p>&bull; The need to rapidly consult her physician if she is thinking of becoming pregnant or there is a possibility of pregnancy.</p><p>In women planning to become pregnant all efforts should be made to switch to appropriate alternative treatment prior to conception, if possible.</p><p>Valproate therapy should only be continued after a reassessment of the benefits and risks of the treatment with valproate for the patient by a physician experienced in the management of epilepsy.</p></td></tr></tbody></table><p><strong><em>Suicidal ideation and behavior:</em></strong></p><p>Suicidal ideation and behavior have been reported in patients treated with anti-epileptic agents in several indications. Data has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for sodium valproate.</p><p>Therefore patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge.</p><p><strong><em>Carbapenem agents:</em></strong></p><p>The concomitant use of valproate and carbapenem agents is not recommended.</p><p><strong>4.4.2 Precautions</strong></p><p><strong><em>Haematological:</em></strong>&nbsp;Blood tests (blood cell count, including platelet count, bleeding time and coagulation tests) are recommended prior to initiation of therapy or before surgery, and in case of spontaneous bruising or bleeding.</p><p><strong><em>Renal insufficiency:</em></strong></p><p>In patients with renal insufficiency, it may be necessary to decrease dosage. As monitoring of plasma concentrations may be misleading, dosage should be adjusted according to clinical monitoring.</p><p><strong><em>Systemic lupus erythematosus:</em></strong>&nbsp;Although immune disorders have only rarely been noted during the use of <strong>EPIVAL<sup>&reg;</sup></strong>, the potential benefit of <strong>EPIVAL<sup>&reg;</sup></strong> should be weighed against its potential risk in patients with systemic lupus erythematosus.<strong><em>&nbsp;</em></strong></p><p><strong><em>Hyperammonaemia:</em></strong>&nbsp;When a urea cycle enzymatic deficiency is suspected, metabolic investigations should be performed prior to treatment because of the risk of hyperammonaemia with <strong>EPIVAL<sup>&reg;</sup></strong>.</p><p><strong><em>Weight gain:</em></strong>&nbsp;<strong>EPIVAL<sup>&reg;</sup></strong> very commonly causes weight gain, which may be marked and progressive. Patients should be warned of the risk of weight gain at the initiation of therapy and appropriate strategies should be adopted to minimise it.</p><p><strong><em>Pregnancy:</em></strong>&nbsp;Women of childbearing potential should not be started on <strong>EPIVAL<sup>&reg;</sup></strong> without specialist neurological advice. Adequate counselling should be made available to all pregnant women with epilepsy of childbearing potential regarding the risks associated with pregnancy because of the potential teratogenic risk to the foetus.</p><p><strong><em>Diabetic patients:</em></strong>&nbsp;<strong>EPIVAL<sup>&reg;</sup></strong> is eliminated mainly through the kidneys, partly in the form of ketone bodies; this may give false positives in the urine testing of possible diabetics.</p><p>In addition, care should be taken when treating diabetic patients with <strong>EPIVAL<sup>&reg;</sup></strong> Syrup since it contains sucrose.</p><p><strong><em>Alcohol:</em></strong>&nbsp;Alcohol intake is not recommended during treatment with valproate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.5.1 Effects of EPIVAL<sup>&reg;</sup> on other drugs</strong></p><p><em>-&nbsp;<strong>Antipsychotics, MAO inhibitors, antidepressants and benzodiazepines</strong></em></p><p><strong>EPIVAL<sup>&reg;</sup></strong> may potentiate the effect of other psychotropics such as antpsychotics, MAO inhibitors, antidepressants and benzodiazepines; therefore, clinical monitoring is advised and the dosage of the other psychotropics should be adjusted when appropriate.</p><p>Adding olanzapine to valproate or lithium therapy may significantly increase the risk of certain adverse events associated with olanzapine e.g. neutropenia, tremor, dry mouth, increased appetite and weight gain, speech disorder and somnolence.</p><p><strong><em>- Lithium</em></strong></p><p><strong>EPIVAL&reg;</strong> has no effect on serum lithium levels</p><p><em>-&nbsp;<strong>Phenobarbital</strong></em></p><p><strong>EPIVAL<sup>&reg;</sup></strong> increases phenobarbital plasma concentrations (due to inhibition of hepatic catabolism) and sedation may occur, particularly in children. Therefore, clinical monitoring is recommended throughout the first 15 days of combined treatment with immediate reduction of phenobarbital doses if sedation occurs and determination of phenobarbital plasma levels when appropriate.</p><p><em>-&nbsp;<strong>Primidone</strong></em></p><p><strong>EPIVAL<sup>&reg;</sup></strong> increases primidone plasma levels with exacerbation of its adverse effects (such as sedation); these signs cease with long term treatment. Clinical monitoring is recommended especially at the beginning of combined therapy with dosage adjustment when appropriate.</p><p><em>-&nbsp;<strong>Phenytoin</strong></em></p><p><strong>EPIVAL<sup>&reg;</sup></strong> decreases phenytoin total plasma concentration. Moreover <strong>EPIVAL<sup>&reg;</sup></strong> increases phenytoin free form with possible overdosage symptoms (valproic acid displaces phenytoin from its plasma protein binding sites and reduces its hepatic catabolism). Therefore clinical monitoring is recommended; when phenytoin plasma levels are determined, the free form should be evaluated.<em>&nbsp;</em></p><p><em>-&nbsp;<strong>Carbamazepine</strong></em></p><p>Clinical toxicity has been reported when <strong>EPIVAL<sup>&reg;</sup></strong> was administered with carbamazepine as <strong>EPIVAL<sup>&reg;</sup></strong> may potentiate toxic effects of carbamazepine. Clinical monitoring is recommended especially at the beginning of combined therapy with dosage adjustment when appropriate.</p><p><em>-&nbsp;<strong>Lamotrigine</strong></em></p><p><strong>EPIVAL<sup>&reg;</sup></strong> reduces the metabolism of lamotrigine and increases the lamotrigine mean half life by nearly two fold. This interaction may lead to increased lamotrigine toxicity, in particular serious skin rashes. Therefore clinical monitoring is recommended and dosages should be adjusted (lamotrigine dosage decreased) when appropriate.</p><p><strong><em>- Felbamate</em></strong></p><p>Valproic acid may decrease the felbamate mean clearance by up to 16%.</p><p><em>-&nbsp;<strong>Zidovudine</strong></em></p><p><strong>EPIVAL<sup>&reg;</sup></strong> may raise zidovudine plasma concentration leading to increased zidovudine toxicity.</p><p><em>-&nbsp;<strong>Vitamin K-dependent anticoagulants</strong></em></p><p>The anticoagulant effect of warfarin and other coumarin anticoagulants may be increased following displacement from plasma protein binding sites by valproic acid. The prothrombin time should be closely monitored.</p><p><em>&nbsp;</em></p><p><em>-&nbsp;<strong>Temozolomide</strong></em></p><p>Co-administration of temozolomide and <strong>EPIVAL<sup>&reg;</sup></strong> may cause a small decrease in the clearance of temozolomide that is not thought to be clinically relevant.</p><p><strong>4.5.2 Effects of other drugs on EPIVAL<sup>&reg;</sup></strong></p><p>Antiepileptics with enzyme inducing effect (including&nbsp;<strong><em>phenytoin, phenobarbital, carbamazepine</em></strong>) decrease valproic acid plasma concentrations. Dosages should be adjusted according to clinical response and blood levels in case of combined therapy.</p><p>On the other hand, combination of&nbsp;<strong><em>felbamate</em></strong>&nbsp;and <strong>EPIVAL<sup>&reg;</sup></strong> decreases valproic acid clearance by 22% to 50% and consequently increase the valproic acid plasma concentrations. <strong>EPIVAL<sup>&reg; </sup></strong>dosage should be monitored.</p><p><strong><em>Mefloquine</em></strong>&nbsp;and&nbsp;<strong><em>chloroquine</em></strong>&nbsp;increase valproic acid metabolism and may lower the seizure threshold; therefore epileptic seizures may occur in cases of combined therapy. Accordingly, the dosage of <strong>EPIVAL<sup>&reg;</sup></strong> may need adjustment.</p><p>In case of concomitant use of <strong>EPIVAL<sup>&reg;</sup></strong> and&nbsp;<strong><em>highly protein bound agents (e.g. aspirin)</em></strong>, free valproic acid plasma levels may be increased.</p><p>Valproic acid plasma levels may be increased (as a result of reduced hepatic metabolism) in case of concomitant use with&nbsp;<strong><em>cimetidine</em></strong>&nbsp;or&nbsp;<strong><em>erythromycin</em></strong>.</p><p><strong><em>Carbapenem&nbsp;antibiotics</em></strong>&nbsp;such as&nbsp;<strong><em>imipenem, panipenem</em></strong>&nbsp;and&nbsp;<strong><em>meropenem</em></strong>: Decreases in blood levels of valproic acid have been reported when it is co-administered with carbapenem agents resulting in a 60%-100% decrease in valproic acid levels within two days, sometimes associated with convulsions. Due to the rapid onset and the extent of the decrease, co-administration of carbapenem agents in patients stabilised on valproic acid should be avoided. If treatment with these these antibiotics cannot be avoided, close monitoring of valproic acid blood levels should be performed.<strong><em>&nbsp;</em></strong></p><p><strong><em>Colestyramine</em></strong>&nbsp;may decrease the absorption of <strong>EPIVAL<sup>&reg;</sup></strong>.</p><p>Rifampicin may decrease the valproic acid blood levels resulting in a lack of therapeutic effect. Therefore, valproate dosage adjustment may be necessary when it is co-administered with rifampicin.</p><p><strong>4.5.3 Other Interactions</strong></p><p>Caution is advised when using <strong>EPIVAL<sup>&reg;</sup></strong> in combination with newer anti-epileptics whose pharmacodynamics may not be well established.</p><p>Concomitant administration of valproate and topiramate has been associated with encephalopathy and/or hyperammonaemia. In patients taking these two drugs, careful monitoring of signs and symptoms is advised in particularly at-risk patients such as those with pre-existing encephalopathy.</p><p><strong>EPIVAL<sup>&reg;</sup></strong> usually has no enzyme-inducing effect; as a consequence, <strong>EPIVAL<sup>&reg; </sup></strong>does not reduce efficacy of oestroprogestative agents in women receiving hormonal contraception, including the oral contraceptive pill.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>EPIVAL<sup>&reg;</sup></strong> should not be used in female children, in female adolescents, in women of childbearing potential and in pregnant women unless other treatments are ineffective or not tolerated. Women of childbearing potential have to use effective contraception during treatment.</p><p>In women planning to become pregnant all efforts should be made to switch to appropriate alternative treatment prior to conception, if possible.</p><p><em>Pregnancy Exposure Risk related to valproate</em></p><p>Both valproate monotherapy and valproate polytherapy are associated with abnormal pregnancy outcomes. Available data suggest that antiepileptic polytherapy including valproate is associated with a greater risk of congenital malformations than valproate monotherapy.</p><p><em>Congenital malformations</em></p><p>Data has shown that some of children of epileptic women exposed to valproate monotherapy during pregnancy suffer from congenital malformations. This is a greater risk of major malformations than for the general population, for whom the risk is about 2-3%. The risk is dose dependent but a threshold dose below which no risk exists cannot be established.</p><p>Available data show an increased incidence of minor and major malformations. The most common types of malformations include neural tube defects, facial dysmorphism, cleft lip and palate, craniostenosis, cardiac, renal and urogenital defects, limb defects (including bilateral aplasia of the radius), and multiple anomalies involving various body systems.</p><p><em>Developmental disorders</em></p><p>Data have shown that exposure to valproate in utero can have adverse effects on mental and physical development of the exposed children. The risk seems to be dose-dependent but a threshold dose below which no risk exists, cannot be established based on available data. The exact gestational period of risk for these effects is uncertain and the possibility of a risk throughout the entire pregnancy cannot be excluded.</p><p>In preschool children exposed in utero to valproate show that up to 30-40% experience delays in their early development such as talking and walking later, lower intellectual abilities, poor language skills (speaking and understanding) and memory problems.</p><p>Intelligence quotient (IQ) measured in school aged children (age 6) with a history of valproate exposure in utero was on average 7-10 points lower than those children exposed to other antiepileptics. Although the role of confounding factors cannot be excluded, there is evidence in children exposed to valproate that the risk of intellectual impairment may be independent from maternal IQ.</p><p>There are limited data on the long term outcomes.</p><p>Available data show that children exposed to valproate in utero are at increased risk of autistic spectrum disorder (approximately three-fold) and childhood autism (approximately five-fold). Limited data suggests that children exposed to valproate in utero may be more likely to develop symptoms of attention deficit/hyperactivity disorder (ADHD).</p><p><em>Female children, female adolescents and woman of childbearing potential </em></p><p><em>If a Woman wants to plan a Pregnancy</em></p><p>&bull; During pregnancy, maternal tonic clonic seizures and status epilepticus with hypoxia may carry a particular risk of death for the mother and the unborn child.</p><p>&bull; In women planning to become pregnant or who are pregnant, valproate therapy should be reassessed</p><p>&bull; In women planning to become pregnant all efforts should be made to switch to appropriate alternative treatment prior to conception, if possible.</p><p>&nbsp;</p><p>Valproate therapy should not be discontinued without a reassessment of the benefits and risks of the treatment with valproate for the patient by a physician experienced in the management of epilepsy. If based on a careful evaluation of the risks and the benefits valproate treatment is continued during the pregnancy, it is recommended to:</p><p>- Use the lowest effective dose and divide the daily dose valproate into several small doses to be taken throughout the day. The use of a prolonged release formulation may be preferable to other treatment formulations in order to avoid high peak plasma concentrations.</p><p>- Folate supplementation before the pregnancy may decrease the risk of neural tube defects common to all pregnancies. However the available evidence does not suggest it prevents the birth defects or malformations due to valproate exposure.</p><p>- To institute specialized prenatal monitoring in order to detect the possible occurrence of neural tube defects or other malformations.</p><p><u>Risk in the neonate</u></p><p>- Cases of haemorrhagic syndrome have been reported very rarely in neonates whose mothers have taken valproate during pregnancy. This haemorrhagic syndrome is related to thrombocytopenia, hypofibrinogenemia and/or to a decrease in other coagulation factors. Afibrinogenemia has also been reported and may be fatal. However, this syndrome must be distinguished from the decrease of the vitamin-K factors induced by phenobarbital and enzymatic inducers. Therefore, platelet count, fibrinogen plasma level, coagulation tests and coagulation factors should be investigated in neonates.</p><p>- Cases of hypoglycaemia have been reported in neonates whose mothers have taken valproate during the third trimester of their pregnancy.</p><p>- Cases of hypothyroidism have been reported in neonates whose mothers have taken valproate during pregnancy.</p><p>- Withdrawal syndrome (such as, in particular, agitation, irritability, hyper-excitability, jitteriness, hyperkinesia, tonicity disorders, tremor, convulsions and feeding disorders) may occur in neonates whose mothers have taken valproate during the last trimester of their pregnancy.</p><p><u>Breastfeeding</u></p><p>Valproate is excreted in human milk with a concentration ranging from 1% to 10% of maternal serum levels. Haematological disorders have been shown in breastfed newborns/infants of treated women. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from <strong>EPIVAL<sup>&reg;</sup></strong> therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.</p><p><u>Fertility</u></p><p>Amenorrhoea, polycystic ovaries and increased testosterone levels have been reported in women using valproate.&nbsp; Valproate administration may also impair fertility in men. Case reports indicate that fertility dysfunctions are reversible after treatment discontinuation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Use of <strong>EPIVAL<sup>&reg;</sup></strong> may provide seizure control such that the patient may be eligible to hold a driving licence. Patients should be warned of the risk of transient drowsiness, especially in cases of anticonvulsant polytherapy or association with benzodiazepines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following CIOMS frequency rating is used, when applicable:</p><p>Very common (&ge; 1/10); Common (&ge; 1/100 to &lt; 1/ 10); Uncommon (&ge; 1/1,000 to &lt;1/100); Rare (&ge; 1/10,000 to &lt;1/1,000); Very rare (&lt;1/10,000), not known (cannot be estimated from available data).</p><p><u>Congenital malformations and developmental disorders</u>&nbsp;.</p><p><u>Hepato-biliary disorders:</u></p><p>Common: liver injury</p><p>Severe liver damage, including hepatic failure sometimes resulting in death, has been reported. Increased liver enzymes are common, particularly early in treatment, and may be transient.</p><p><u>Gastrointestinal disorders:</u></p><p>Very common: nausea,</p><p>Common: gastralgia, diarrhoea</p><p>The above three adverse events frequently occur at the start of treatment, but they usually disappear after a few days without discontinuing treatment. These problems can usually be overcome by taking <strong>EPIVAL<sup>&reg;</sup></strong> with or after food or by using Enteric Coated <strong>EPIVAL<sup>&reg;</sup></strong> (<strong>EPIVAL<sup>&reg;</sup></strong> Gastro-resistant tablets).</p><p>Uncommon: pancreatitis, sometimes lethal.</p><p><u>Nervous system disorders:</u></p><p>Very common: tremor</p><p>Common: extrapyramidal disorder, stupor*, somnolence, convulsion*, memory impairment, headache, nystagmus,</p><p>Uncommon: coma*, encephalopathy, lethargy*, reversible parkinsonism, ataxia, paresthesia.</p><p>Rare: reversible dementia associated with reversible cerebral atrophy, cognitive disorder.</p><p>&nbsp;</p><p>Sedation has been reported occasionally, usually when in combination with other anticonvulsants. In monotherapy it occurred early in treatment on rare occasions and is usually transient.</p><p>*Rare cases of lethargy occasionally progressing to stupor, sometimes with associated hallucinations or convulsions have been reported. Encephalopathy and coma have very rarely been observed. These cases have often been associated with too high a starting dose or too rapid a dose escalation or concomitant use of other anticonvulsants, notably phenobarbital or topiramate. They have usually been reversible on withdrawal of treatment or reduction of dosage.</p><p>An increase in alertness may occur; this is generally beneficial but occasionally aggression, hyperactivity and behavioural deterioration have been reported.</p><p><u>Psychiatric disorder:</u></p><p>Common: confusional state, aggression*, agitation*, disturbance in attention*</p><p>Rare: abnormal behaviour*, psychomotor hyperactivity*, learning disorder*</p><p>*These ADRs are principally observed in the paediatric population.</p><p><u>Metabolic disorders:</u></p><p>Common: hyponatraemia.</p><p>Rare: hyperammonaemia*</p><p>&nbsp;</p><p>*Cases of isolated and moderate hyperammonaemia without change in liver function tests may occur, are usually transient and should not cause treatment discontinuation. However, they may present clinically as vomiting, ataxia, and increasing clouding of consciousness. Should these symptoms occur <strong>EPIVAL<sup>&reg;</sup></strong> should be discontinued.</p><p>Hyperammonaemia associated with neurological symptoms has also been reported. In such cases further investigations should be considered.</p><p><u>Endocrine Disorders:</u></p><p>Uncommon: Syndrome of Inappropriate Secretion of ADH (SIADH)</p><p>Rare: hypothyroidism</p><p><u>Blood and lymphatic system disorders:</u></p><p>Common: anaemia, thrombocytopenia.</p><p>Uncommon: pancytopenia, leucopenia</p><p>The blood picture returned to normal when the drug was discontinued.</p><p>Rare: bone marrow failure, including pure red cell aplasia, agranulocytosis, anaemia macrocytic, macrocytosis</p><p>Isolated findings of a reduction in blood fibrinogen and/or an increase in prothrombin time have been reported, usually without associated clinical signs and particularly with high doses (<strong>EPIVAL<sup>&reg;</sup></strong> has an inhibitory effect on the second phase of platelet aggregation). Spontaneous bruising or bleeding is an indication for withdrawal of medication pending investigations.</p><p><u>Skin and subcutaneous tissue disorders:</u></p><p>Common: hypersensitivity, transient and or dose related alopecia (hair loss). Regrowth normally begins within six months, although the hair may become curlier than previously.</p><p>Uncommon: angioedema, rash</p><p>Hirsutism and acne have been very rarely reported.</p><p>Rare: toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome.</p><p><u>Reproductive system and breast disorders:</u></p><p>Common: dysmenorrhea</p><p>Uncommon: amenorrhea</p><p>Rare: male infertility, polycystic ovaries</p><p>Very rarely gynaecomastia has occurred.</p><p><u>Vascular disorders:</u></p><p>Common: haemorrhage.</p><p>Uncommon: vasculitis</p><p><u>Ear and labyrinth disorders:</u></p><p>Common: Deafness, a cause and effect relationship has not been established.</p><p><u>Renal and urinary disorders:</u></p><p>Rare: enuresis, reversible Fanconi syndrome (a defect in proximal renal tubular function giving rise to glycosuria, amino aciduria, phosphaturia, and uricosuria) associated with <strong>EPIVAL<sup>&reg;</sup></strong> therapy, but the mode of action is as yet unclear.</p><p><u>General disorders and administration site conditions:</u></p><p>Uncommon: non-severe oedema peripheral</p><p><u>Musculoskeletal and connective tissue disorders:</u></p><p>Uncommon: bone mineral density decreased, osteopenia, osteoporosis and fractures in patients on long-term therapy with <strong>EPIVAL<sup>&reg;</sup></strong>. The mechanism by which <strong>EPIVAL<sup>&reg;</sup></strong> affects bone metabolism has not been identified.</p><p>Rare: systemic lupus erythematosus</p><p><u>Respiratory, thoracic and mediastinal disorders:</u></p><p>Uncommon: pleural effusion</p><p><u>Investigations:</u></p><p>Common: Weight increased*</p><p>Rare: Coagulation factors decreased (at least one), abnormal coagulation tests (such as prothrombin time prolonged, activated partial thromboplastin time prolonged, thrombin time prolonged, INR prolonged).</p><p>*Weight increase should be carefully monitored since it is a factor for polycystic ovary syndrome <u>Neoplasms benign, malignant and unspecified (including cysts and polyps):</u></p><p>Rare: myelodysplastic syndrome.</p><p>&nbsp;</p><p><strong>To report any side effect(s): </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia: </strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp; National Pharmacovigilance &amp; Drug Safety Centre (NPC):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222, Ext.: 2317-2356-2353-2354-2334-2340.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Toll free phone : 8002490000</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>-&nbsp;&nbsp; <strong>Other GCC States: </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:678px"><tbody><tr><td style="vertical-align:top"><p>Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Signs and Symptoms:</strong></p><p>Cases of accidental and deliberate Sodium valproate overdosage have been reported. At plasma concentrations of up to 5 to 6 times the maximum therapeutic levels, there are unlikely to be any symptoms other than nausea, vomiting and dizziness.</p><p>Signs of massive overdose, i.e. plasma concentration 10 to 20 time&rsquo;s maximum therapeutic levels, usually include CNS depression or coma with muscular hypotonia, hyporeflexia, miosis, impaired respiratory function, metabolic acidosis. A favourable outcome is usual; however some deaths have occurred following massive overdose.</p><p>Symptoms may however be variable and seizures have been reported in the presence of very high plasma levels.</p><p>Cases of intracranial hypertension related to cerebral oedema have been reported.</p><p><strong>Management:</strong></p><p>Hospital management of overdose should be symptomatic:, including cardio-respiratory monitoring. Gastric lavage may be useful up to 10 to 12 hours following ingestion.</p><p>Haemodialysis and haemoperfusion have been used successfully.</p><p>Naloxone has been successfully used in a few isolated cases, sometimes in association with activated charcoal given orally. In case of massive overdose, haemodialysis and haemoperfusion have been used successfully.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group:</strong> Sodium valproate is an anticonvulsant.</p><p><strong>ATC code: N03AG01</strong></p><p>The most likely mode of action for <strong>EPIVAL<sup>&reg; </sup></strong>&nbsp;is potentiation of the inhibitory action of gamma amino-butyric acid (GABA) through an action on the further synthesis or further metabolism of GABA.</p><p>In peripheral blood mononuclear cells from HIV-infected patients show that<strong> EPIVAL<sup>&reg;</sup></strong> does not have a mitogen-like effect on inducing HIV replication. Indeed the effect of <strong>EPIVAL<sup>&reg;</sup></strong> on HIV replication&nbsp;<em>ex-vivo&nbsp;</em>is highly variable, modest in quantity, appears to be unrelated to the dose and has not been documented in man.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The half-life of <strong>EPIVAL<sup>&reg;</sup> </strong>is usually reported to be within the range 8-20 hours. It is usually shorter in children.</p><p>In patients with severe renal insufficiency it may be necessary to alter dosage in accordance with free plasma valproic levels.</p><p>The reported effective therapeutic range for plasma valproic acid levels is 40-100mg/litre (278-694micromol/litre). This reported range may depend on time of sampling and presence of co-medication.</p><p>&nbsp;</p><p>The percentage of free (unbound) drug is usually between 6% and 15% of the total plasma levels. An increased incidence of adverse effects may occur with plasma levels above the effective therapeutic range.</p><p>The pharmacological (or therapeutic) effects of <strong>EPIVAL<sup>&reg;</sup></strong> may not be clearly correlated with the total or free (unbound) plasma valproic acid levels.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>&Oslash;&nbsp; Sucrose</p><p>&Oslash;&nbsp; Usacert FD&amp;C red No. 40</p><p>&Oslash;&nbsp; Cherry Flavor Liquid</p><p>Purified Water Q.S.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C. Discard the content after one month from first opening.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>EPIVAL&reg; 200mg/5ml Syrup</strong> is packed in Amber glass bottles type III soda lime glass, white cylindrical, Polypropylene inner and outer caps, LD polypropylene ring and insert, child resistant, the bottles are labeled with colored adhesive labels packaged in carton boxes with a multi folded leaflets &amp; a Translucent polypropylene dosing spoon.</p><p><strong>&nbsp;</strong></p><p><strong>Pack size: EPIVAL<sup>&reg;</sup> 200mg/5ml Syrup</strong> is available in the pack size of 100 ml bottles.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The United Pharmaceutical Mfg. Co Ltd.
P.O. Box 69, Amman 11591-Jordan
Tel: + 962 (6) 416 2901      
Fax: + 962 (6) 416 2905 
E-mail:  Info@upm.com.jo

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Feb., 2015
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>